



ISSN: 1697-090X

Inicio Home

Indice del
volumen Volume
index

Comité Editorial
Editorial Board

Comité Científico
Scientific
Committee

Normas para los
autores
Instruction to
Authors

Derechos de autor
Copyright

Contacto/Contact:



PHYSIOPATHOLOGY OF ACUTE RENAL FAILURE. NEW CLUES FOR AN OLD DILEMMA

Carlos G. Musso¹ Juliana Reynaldi², Juan F. Macías Núñez²

¹Nephrology Division. Hospital Italiano de Buenos Aires. Argentina

²Nephrology Division. Hospital Universitario de Salamanca. España.

[carlos.musso @ hospitalitaliano.org.ar](mailto:carlos.musso@hospitalitaliano.org.ar)

Rev Electron Biomed / Electron J Biomed 2008;1:67-71

[Version en español](#)

[Comment of the reviewer Abdías Hurtado Arístegui, MD, DM.](#) Hospital Arzobispo Loayza. Universidad Peruana Cayetano Heredia. Lima, Peru.

[Comment of the reviewer Secundino Cigarrán Guldrís, MD.](#) Servicio de Nefrología - Complejo Hospitalario Universitario de Vigo. Pontevedra. España

SUMMARY

Acute renal failure (ARF) is the term used to describe the sustained and abrupt reduction of the glomerular filtration, which causes the retention of waste products that come from the metabolism. Normally, the mechanisms potentially involved in ARF are divided into: pre-renal, parenchymatous, and post-renal. Regarding the etiology of the parenchymatous ARF, it would seem to be the sum of multiple pathogenic variables such as: tubular necrosis and apoptosis, alteration of the filtration barrier, retrodiffusion of glomerular filtration, intrarenal vasoconstriction, contraction of the mesangium, intratubular obstruction, interstitial swelling, activation of proteolytic enzymes, and so on. Because of the above exposed data, only a multicausal perspective would seem to be adequate to understand and solve this syndrome.

KEY WORDS: Acute renal failure, glomerular filtration

RESUMEN

Insuficiencia renal aguda (IRA) es el término con el cual se designa a la reducción abrupta y sostenida del filtrado glomerular, de la cual resulta la retención de productos de desecho del metabolismo corporal. Clásicamente se dividen los mecanismos de la IRA en pre-renal, parenquimatoso, y obstructivo. En el caso de la IRA parenquimatosa, ésta pareciera ser el resultado de la sumatoria de las múltiples variables: necrosis y apoptosis tubular, alteración de la barrera de filtración, retrodifusión del filtrado glomerular, vasoconstricción intra-renal, contracción del mesangio, obstrucción intratubular, inflamación intersticial, activación de enzimas proteolíticas, entre otros. Por este motivo se postula que sólo una mirada de perspectiva multicausal de este síndrome pareciera ser la estrategia adecuada para conseguir su entendimiento cabal y tendiente a la resolución del mismo.

PALABRAS CLAVE: Insuficiencia renal aguda, filtrado glomerular

INTRODUCTION

Acute renal failure (ARF) is the term used to describe the sustained and abrupt reduction of the glomerular filtration, which causes the retention of waste products that come from the metabolism¹⁻³.

Although currently a universal definition for this syndrome has not been found, it is reasonable to take as a parameter for its detection, the documentation of a sustained and acute increase of 0.5 mg/dl in basal serum creatinine, if it is lower than 2,5 mg/dl, or an increase higher than 20%, if its basal value is higher than 2,5 mg/dl^{1,2,4}.

Normally, the mechanisms potentially involved in ARF are divided into:

1. Fall of the renal flow preserving the integrity of the parenchyma (pre-renal ARF)⁵⁻⁹.
2. Acute renal parenchymatous damage (intrinsic ARF)¹⁰⁻¹⁴.
3. Urinary flow obstruction (post renal ARF)¹⁵⁻¹⁶.
4. Mixed^{15,17-18}.

Regarding the etiology of the parenchymatous ARF, after more than half a century of research a central physiopathological mechanism has not been found, which would seem to be the sum of the multiple pathogenic variables displayed in such condition. Below we will discuss each one of these variables we know about thanks to experimental models (based on the use of ischemic or toxic agents) carried out mainly on rodents:

- a) Tubular necrosis: any of the renal damaging agents can lead to the death of the tubular cells due to damage of at least one of its constitutive elements: cellular membrane, lysosomes, etc causing the condition known as *acute tubular necrosis* (ATN). However, the number of necrotic cells is not enough to justify renal failure per se which is characteristic of this syndrome¹⁰⁻¹⁴.
- b) Tubular Apoptosis: In recent years, some authors have stressed the importance not only of the induction of tubular necrosis inducing agents in the physiopathology of ARF, but also of the phenomenon which prematurely activates the usual programmed cellular death mechanism or apoptosis, thus adding the concept of *cellular apoptosis* to the typical ATN¹⁵.
- c) Alteration of the filtration barrier: A reduction in the length and density has been documented at the level of the endothelial pores of the glomerulus¹⁹⁻²¹.
- d) Retrodiffusion of glomerular filtration: Another of the mechanisms which participates in the decrease of the renal function is the retrodiffusion of glomerular filtration as a result of the alteration of the Starling's forces around the proximal tubules. Therefore, most of the initially filtrated substances are reabsorbed returning immediately to the vascular compartment, thus making the filtration ineffective^{16,22}.
- e) Intrarenal vasoconstriction: This mechanism is to some extent responsible for the decrease of glomerular filtration characteristic of the parenchymatous ARF, but it is not its main cause since the magnitude of the decrease is lower than the filtration one, and even re-establishing the renal perfusion is usually not only accompanied by the persistence of the decrease in glomerular filtration but also of a more serious damage²³⁻²⁸.
- f) Contraction of the mesangium: Mesangial cells are contracted generating a reduction of the Kf (ultrafiltration coefficient), which helps reducing the filtration surface²⁹.
- g) Disbalance between vasoconstrictor and vasodilator substances: The arteriolar vasoconstriction and mesangial contraction mechanisms already mentioned are stimulated by a local of vasoconstrictor substances (angiotensin II, platelet activating factor (PAF), adenosine, endothelin 1, A2 thromboxane, etc) and a reduction of the vasodilators (prostaglandine E2, nitric oxide, etc) which occurs during ARF^{23-28, 30}.
- h) Intratubular obstruction: In parenchymatous ARF, the tubular cells redistribute their integrins (adhesion molecules

of the cellular membrane) which move away from its usual position (capillary pole) and relocate in the apical pole. This phenomenon contributes to the intratubular obstruction phenomenon because the tubular cells, not so adhered now to the basal membrane, fall towards the tubular light where despite its integrins, they adhere among them, as well as to the apical face of those which are still adhered to the basal membrane. Generally the Tam-Horsfall tubular protein is added to this conglomerate, which increases the volume of these cellular plugs thus increasing its obstructive power ²².

i) **Interstitial swelling:** The inflammatory cells would be recruited at the renal interstitial level due to the local release of cytokines (e.g. alfa TNF, etc) via a hypoxic or toxic stimulus. Such infiltration would generate an edema and compromise of the local microcirculation ¹⁵.

j) **Activation of proteolytic enzymes:** Tissue ischemia leads to an increase in the levels of intracellular calcium, which would have a bad effect in the tubular cells. Intracellular calcium triggers the activation of enzymes which damage sub-cellular structures: For example, this is how calpain is activated, a protease which damages the tubular cytoskeleton. This observation has made some authors propose the use of calcium blockers in parenchymatous ARF¹⁵.

k) **Oxidative stress:** The damaging agents which can produce parenchymatous ARF are also exciters of histotoxic metabolites derived from oxygen ³¹.

l) **Tissue growth factors:** Cellular damage stimulates several growth factors which contribute to the regeneration of necrotic tubular cells, even some of them, such as IGF or EGF have demonstrated its effectiveness when used exogenously in animal models of ARF. Nevertheless, the activity of some of these factors can contribute to the generation of excessive fibrosis during the repairing processes ³²⁻³³.

From what was discussed above we can obtain two main conclusions:

- The three physiopathological mechanisms proposed to interpret the generation of an ARF: decreased flow, tissue damage and obstruction appear, to some extent, together in parenchymatous ARF.
- Definitely, a monocausal physiopathological model, as it was thought in the past century, cannot cause a complex phenomena such as acute renal failure ³⁴⁻³⁵. Only a multicausal perspective would seem to be adequate to understand and solve this syndrome.

REFERENCES

1. Racusen LC. The morphologic basis of acute renal failure. In: *Acute renal failure: A comparison to Brenner and Rector's The Kidney*. Molitoris BA, Finn WF, editors. Philadelphia: W.B. Saunders, 2001; 1-12
2. Stein JH, Lifschitz BD, Barnes LD. Current concepts on the pathophysiology of acute renal failure. *Am J Physiol* 1978; 234:F171-81
3. Musso C, Macías-Núñez JF. Renal disease. In: *Principles and Practice of Geriatric Medicine*. Pathy MSJ, Sinclair AJ, Morley, J.E editors. Chichester: John Wiley and sons. 2006;1496-1506.
4. Lamiere NH, Van Den Noortgate N, Vanholder RC. Acute renal failure in the elderly. In: *Oxford Textbook of Clinical Nephrology*. Davison A, Cameron JS, Grünfeld JP, Ponticelli C, Ritz E, Winearls, C.G, Van Ypersele Ch, editors. Oxford: Oxford University Press 2005;1630-1644
5. Solez K, Altman J, Rienhoff H et al.: Early angiographic and renal blood flow changes after HgCl₂ or glycerol administration. *Kidney Int* 1976; 10:S153-S159
6. Hsu CH, Kurtz TW, Rosenzweig J, Weller JM: Renal hemodynamics in HgCl₂-induced acute renal failure. *Nephron* 1977; 18:326-332
7. Goormaghtigh N. Existence of an endocrine gland in the arteriolar media of renal arterioles. *Proc Soc Exp Biol Med* 1939; 42: 688-9
8. López-Novoa JM, Casado S, Hernando L: Protection by propranolol against Glycerol-induce acute renal failure. Role of extracellular volume expansion. *Biomedicina* 1978; 29:303-306.
9. Macias-Núñez JF, Lopez Novoa JM, Martinez Maldonado, M. Acute renal failure in the aged. *Seminars in Nephrology*

1996;16: 330-338

10. Flamenbaum W, McNeil JS, Kotchen TW, Saladino AJ. Experimental acute renal failure induced by uranyl nitrate in the dog. *Circ Res* 1972; 31:682-698
11. Venkatachalam MA, Bernard BD, Donohoe JF y Levinsky NG. Ischemic damage and repair in the rat proximal tubule: differences among the S1, S2 and S3 segments. *Kidney Int* 1978; 14:31-49
12. Baylis C, Rennke HG, Brenner BM: Mechanisms of the defect in glomerular ultrafiltration associated with gentamicin administration. *Kidney Int* 1977; 12:344-353
13. Schor N, Ichikawa I, Rennke HG et al.: Pathophysiology of altered glomerular function in aminoglycoside-treated rats. *Kidney Int* 1981; 19:288-296
14. Aspelin P, Aubry P, Franson S et al. Nephrotoxic effects in high risk patients undergoing angiography. *N. Engl.J. Med* 2003;348:491-9.
15. Lameire NH and Vanholder RC. Acute renal failure: Pathophysiology and prevention. In: *Oxford Textbook of Clinical Nephrology*. Davison A, Cameron JS, Grünfeld JP, Ponticelli C, Ritz E, Winearls, C.G, Van Ypersele Ch, editors. Oxford: Oxford University Press 2005;1445-1464
16. Mason J, Olbricht C, Takabatake T, Thureau K: The early phase of experimental acute renal failure. Intratubular pressure and obstruction. *Pflügers Arch* 1977; 370:155-163
17. Akposso K, Hertig A, Couprie R et al. Acute renal failure in patients over 80 years old: 25 years' experience. *Intensive care medicine*.2000; 26: 400-406).
18. Macías JF, Sánchez Tomero J.A. Acute renal failure in old people. In: *Renal function and disease in the elderly*. Macias Núñez JF, Cameron J.S, editors. London: Butterworths, 1987; 461-484
19. Rodriguez Mañas L. Aging and the Vascular Wall *Circulation* 200,104:2638-40.
20. Avasthi P, Evan AP, Hay D: Glomerular endothelial cells in uranyl nitrate-induced acute renal failure in rats. *J Clin Invest* 1980; 65:121-127
21. Ramos B, López-Novoa JM y Hernando L: Role of hemodynamic alterations in the partial protection afforded by uninephrectomy against glycerol-induced acute renal failure in rats. *Nephron* 1982; 30: 68-72
22. Donohoe JF, Venkatachalam MA, Bernard DB, Levinsky NG: Tubular leakage and obstruction after renal ischemia: structure-function correlations. *Kidney Int* 1978; 13:208-222
23. Werb R, Clark WF, Lindsay RM et al.: Protective effect of prostaglandin (PGE2) in glycerol-induced acute renal failure in rats. *Clin Sci Mol Med* 1978; 55:505-507
24. Mauk RH, Patak RV, Fadem SZ et al.: Effect of prostaglandin E administration in a nephrotoxic and a vasoconstrictor model of acute renal failure. *Kidney Int* 1977;12:122-130
25. Role of endothelin in the pathogenesis of hypertension. Perez del Villar C, Garcia Alonso C J, Feldstein CA, Luncos LA, Romero JC. *Mayo Clin Proc.* 2005;80:84-96
26. Garcia RE. Therapeutic strategies in the prevention of acute renal failure. *Ren. Fail.* 1997; 19: 231-235.
27. Tsau YK, Tsai WS, Chen Ch. Urinary endothelin-1 in children with acute renal failure of tubular origin. *J. Fromo. Med Assoc* 1998; 97: 387-391
28. Macías JF, García Iglesias C, Santos JC, Villamediana LM, López-Novoa J.M: Influence of plasma renin content, intrarenal angiotensin II, captopril and calcium channel blockers on the vasoconstriction and renin release promoted by adenosine in the kidney. *J Lab Clin Med* 1985; 106: 562-567
29. Martínez-Salgado C, Rodríguez-Barbero A, Rodríguez-Puyol D, Pérez de Lema G, López-Novoa JM: Involvement of phospholipase A2 in gentamicin-induced rat mesangial cell activation. *Am. J. Physiol* 1997; 273: F60-F66

30. Kolonko A, Wiecek A, Kokot F: The nonselective adenosine antagonist theophylline does prevent renal dysfunction induced by radiographic contrast agents. *J Nephrol* 1998; 11:151-156
31. Valdivielso JM, Rivas cabañero L, Perez-Barriocanal F, Lopez-Novoa JM: Effect of nitric oxide synthesis modification on renal function in gentamicin-induced nephrotoxicity. *Environ Toxicol Pharmacol* 1997; 3: 123-128
32. López-Novoa JM: Potential role of platelet activating factor in acute renal failure, *Kidney Int* 1999; 55: 1672-1682.
33. Griño JM. BN 52021: A platelet activating factor antagonist for preventing post-transplant renal failure. A double-blind, randomized study. *Ann Intern Med* 1994; 121:345-347
34. Mirolí A. La medicina en el tiempo. Buenos Aires. El Ateneo. 1978
35. Escuela Nacional de Salud Pública. La causalidad compleja: ¿un nuevo paradigma causal en epidemiología?. *Rev Cubana Salud Publica* 2004; 30(3): 1-10

Comentario del revisor Abdías Hurtado Aréstegui MD. PhD. Hospital Arzobispo Loayza. Universidad Peruana Cayetano Heredia. Lima, Peru

Acute renal failure is a syndrome which have been defined as a rapid (in hours or days) renal function reduction. Since this syndrome can be caused by several sort of diseases, there are many physiopathologic mechanisms involved in its installation.

Several hypothesis have been proposed to explain acute renal failure etiology which are based on information obtained from experimental models: hemodynamic alterations (Kf reduction, vasoconstriction, medulla congestion), tubular injury (back-filtration, intratubular obstruction), and those proposed by molecular biology such as cytoskeleton damage or cellular polarity alteration¹⁻². The above review of Musso et al, lists the changes which have been described in these pilot studies.

1.- Bonventre JV. Pathophysiology of acute kidney injury: roles of potential inhibitors of inflammation. *Contrib Nephrol.* 2007; 156: 39-46.

2.- Lameire N. The pathophysiology of acute renal failure. *Crit Care Clin.* 2005; 21:197-210

Comentario del revisor Secundino Cigarran Guldrís, MD. Servicio de Nefrología - Complejo Hospitalario Universitario de Vigo. Pontevedra. España

In this article Musso et al. deliver in an academic, clear and brief way an up to date of the physiopathologic mechanisms involved in acute renal failure development and perpetuation.

The delivered information is based on data which comes from basic and clinical reaserch.

Received: December 26, 2007.

Published February 29, 2008.